Multiple myeloma (MM) is a hematological malignancy that exhibits aberrantly high levels of
proteasome activity. While treatment with the proteasome inhibitor bortezomib substantially …

Background & aims Although bortezomib as one of the first line medicines that has greatly
improved the overall survival of patients with multiple myeloma (MM), undesired drug …

The n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) have been shown to enhance the effect of chemotherapeutic drugs in clinical …

Background The proteasome inhibitor bortezomib (BTZ) is successfully applied in the
treatment of multiple myeloma, but its efficacy is restricted by the wide-spread occurrence of …

The proteasome inhibitor bortezomib (BTZ) has emerged as an effective drug for the
treatment of multiple myeloma even though many patients relapse from BTZ therapy. The …

Background and Purpose Aberrant lipid metabolism is recognized as a key feature of cancer
cells. Our initial research on MS‐based analysis of lipids in a multiple myeloma (MM) cell …

Resistance to the proteasome inhibitor bortezomib (BTZ) represents a major obstacle in the
treatment of multiple myeloma (MM). The contribution of lipid metabolism in the resistance of …

Multiple myeloma (MM) is the second most common hematological malignancy worldwide,
characterized by abnormal proliferation of malignant plasma cells within a tumor-permissive …

During the development of drug resistance, multiple myeloma (MM) cells undergo changes
to their metabolism. However, how these metabolic changes can be exploited to improve …

Multiple myeloma is an incurable plasma cell malignancy with only a 53% 5-year survival
rate. There is a critical need to find new multiple myeloma vulnerabilities and therapeutic …